Indonesia says to secure Sinopharm COVID-19 vaccine for private use

BPOM did not respond to a request for comment. At the same forum, State-owned enterprises minister Erick Thohir said more than 6,600 companies had signed up for the private scheme, which some health experts have criticised because of concern it could worsen vaccine inequity.

Reuters | Jakarta | Updated: 25-02-2021 11:07 IST | Created: 25-02-2021 11:07 IST
Indonesia says to secure Sinopharm COVID-19 vaccine for private use

Indonesia will receive at least two million doses of a coronavirus vaccine produced by China's Sinopharm for use in a private vaccination scheme due to run alongside a national inoculation programme, a minister said on Thursday. Indonesia, which has faced one of the biggest COVID-19 outbreaks in Asia, aims to vaccinate 181.5 million people within about a year using vaccines made by companies such as Sinovac Biotech, Novavax and AstraZeneca.

Luhut Binsar Pandjaitan, Indonesia's minister for maritime affairs and investment, said the China National Pharmaceutical Group (Sinopharm) vaccine would be part of the private scheme. "What's fixed is two million (doses). Three million is our hope...we will vaccinate employees in stages," he told an economic forum.

The private plan has been pushed by Indonesian business as a way for companies to buy vaccines from the government so that their employees can be vaccinated in order to help prop up the country's battered economy. The private plan is due to use alternative vaccines from the ones currently being used and the government is preparing a regulation.

Bambang Heriyanto, corporate secretary of Bio Farma, a state-owned pharmaceutical company in charge of procuring vaccines, said talks were still ongoing with Sinopharm and the vaccine needed approval from the food and drugs agency (BPOM). BPOM did not respond to a request for comment.

At the same forum, State-owned enterprises minister Erick Thohir said more than 6,600 companies had signed up for the private scheme, which some health experts have criticised because of concern it could worsen vaccine inequity. Sinopharm did not immediately respond to a request for comment.

Sinopharm affiliate, the Wuhan Institute Of Biological Products, said on Wednesday its vaccine had an efficacy rate of 72.51% against COVID-19, citing interim analysis of late-stage clinical trial data, without offering more details.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Viral variants and vaccine nationalism pose two-pronged threat to Covid victory

... ...

Tracking Fintech during COVID-19: Harnessing power of technology

Its abundantly clear now that as fintech cements its place in the financial sector, accelerated further by the COVID-19 pandemic, it could open the sector to new possibilities by harnessing the power of technology to deliver financial ...

Tectonic turns: How technology shaped healthcare over the decades

Tracing an episodic evolution, with technology at the interface of human and his health....

World Water Day sees crises of inequality in countries both rich and poor

... ...

Videos

Latest News

Tara Sutaria, Arjun Kapoor commence shoot for 'Ek Villain Returns'

Bollywood actor Tara Sutaria and Arjun Kapoor, on Saturday announced that they have started shooting for their upcoming romantic thriller Ek Villain Returns. Tara took to her Instagram story and shared the news by posting a boomerang video ...

PM Modi requests to keep Haridwar Kumbh 'symbolic', inquires about health of seers

A day after 30 sadhus tested positive for COVID-19 amidst the Kumbh Mela in Haridwar, Prime Minister Narendra Modi on Saturday said he spoke to Swami Avdheshanand Giri, Acharya Mahamandleshwar, Juna Akhara to inquire about the health of the...

Indian pharma exports grow at 18 percent to 24.44 bn in FY 21

Pharma exports from India witnessed over 18 per cent growth to USD 24.44 billion during the last financial year against USD 20.58 billion in FY20, Pharmaceuticals Export Promotion Council of India Pharmexcil said on Saturday.We have observe...

Odd News Roundup: Meet Messi, the Russian puma; Malaysian farmers attempt to grow prized Japanese muskmelons and more

Following is a summary of current odd news briefs.Music and massage Malaysian farmers attempt to grow prized Japanese muskmelonsAfter more than a decade of experimenting, a trio of Malaysian farmers says they have found the right concoction...

Give Feedback